- Home
- NVCR vs TSHA Comparison
NVCR vs TSHA Comparison
Compare NVCR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCR | TSHA |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVCR | TSHA |
|---|---|---|
| Price | $10.51 | $4.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $26.42 | $10.56 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $642,269,000.00 | $6,310,000.00 |
| Revenue This Year | $10.64 | N/A |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $9.82 | $1.05 |
| 52 Week High | $22.95 | $6.02 |
Technical Indicators
Market Signals| Indicator | NVCR | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 43.08 |
| Support Level | $9.82 | $4.40 |
| Resistance Level | $12.91 | $4.70 |
| Average True Range (ATR) | 0.62 | 0.25 |
| MACD | -0.33 | -0.00 |
| Stochastic Oscillator | 13.91 | 13.10 |
Price Performance
Historical ComparisonAbout NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.